American College of Cardiology (ACC) 2021

Mediation Analysis for Dapagliflozin and the Reduction in Hospitalization for Heart Failure in DECLARE-TIMI 58

Clinical Profiles, Medical Therapies, and Outcomes Among Patients Hospitalized for HF Across the Spectrum of Kidney Function: The GWTG-HF Registry

Dapagliflozin attenuates endothelial leak via an apolipoprotein m-dependent pathway

Effects Of Dapagliflozin On Prevention Of Major Clinical Events And Recovery In Patients With Respiratory Failure Due To COVID-19 - Main Results From The DARE-19 Randomized Trial

Leisure-time physical activity associates favorably with the bioactive lipidome and risk of incident CVD events: Results from the VITamin D and OmegA-3 TriaL (VITAL) and JUPITER trials

Rationale and Design for a Phase 2 trial of Verinurad plus Allopurinol in Patients with Heart Failure with Preserved Ejection Fraction and Hyperuricemia

Efficacy, safety and tolerability of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: a phase 2a study (FLAVOUR)

The safety and efficacy of single and multiple ascending doses of MEDI6570 in participants with type 2 diabetes mellitus

Cardioprotection and plaque regression with MEDI6012 in acute ST elevation myocardial infarction - primary results of the REAL-TIMI 63B randomized clinical trial

Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): long-term follow-up of a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol